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Abstract Objectives. This study aims to evaluate the effects of methylphenidate (MPH) on eating         
patterns and body mass index (BMI) in children with attention deficit/hyperactivity disorder 
(ADHD). The secondary aim of this study is the comparison between weight and eating behavior 
of children with ADHD undergoing an MPH treatment, and of children without ADHD. 
Methods. One hundred fourty three children and adolescents who diagnosed with ADHD were 
enrolled, and the effects of MPH on the eating patterns and BMI were evaluated. All participants 
completed a number of tests to analyze eating patterns and clinical psychopathological profiles. 
Results. Children and adolescents with ADHD had significantly higher scores on the EDE-Q- 
eating concern, EDE-Q- shape concern, and all CPRS-RSF subscales than individuals without 
ADHD (p < .05).  MPH treatment was associated with a notional reduction in height-sds and 
weight-sds. The results of the correlation analysis which assessed the possible contribution of the 
different treatment-related factors revealed no significant correlations between MPH mean dose 
[mg/(kg/d)], the duration of use (months), and the core characteristics of eating disorders except the 
restraint subscale of EDE Q. 
Conclusions. Our findings add to the growing research suggesting that MPH may be associated 
with disordered eating behaviors. Although the literature is limited, our findings conclude that MPH 
may not be associated with the reduction of growth velocity and disordered eating behaviors. 
Keywords  Methylphenidate, eating patterns, height, weight, BMI 
Highlights ✓ Patients with ADHD have significantly higher scores from the EDE-Q- eating concern, 
EDE-Q- shape concern and all CPRS-RSF subscales than individuals without ADHD. 
✓ EDE-Q shape concern and CPRS-RSF subscale scores seem to be correlated with 
inattention and cognitive problems. 
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Introduction 
Attention Deficit Hyperactivity Disorder (ADHD) is 
defined as a neurodevelopmental disorder that reflects the 
persistence of ADHD symptoms such as inattention, 
overactivity, and impulsivity across the lifespan (1). 
Children with ADHD are at elevated risk of comorbid 
psychopathology such as mood disorders, anxiety 
disorders, substance use disorders, learning disorders, and 
conduct disorders (2). Some studies also suggest a possible 
link between ADHD and an increased risk of eating 
disorders, specifically that eating disorders and ADHD 
may share common clinical features and that ADHD rates 
may increase eating disorders and/or contribute to the 
seriousness of pathological eating behaviors (3). 
Biederman et al. (2010) reported that girls treated for 
ADHD in childhood and adolescence were 3.5 times more 
likely to be diagnosed with eating disorders than girls 
without ADHD in young adulthood (95% CI: 1.6-7.3) (4). 
Similarly, Yoshimasu et al. found that children with 
ADHD were 5.7 times more likely to have eating disorders 
than those without ADHD (95% CI: 1.1-28.2) in late 
adolescence, based on data from a population-based birth 
cohort (5). Childhood ADHD symptoms have been 
associated with the development of irregular eating 
behaviors including bulimic symptoms, binge eating, and 
restrictive eating in the present and subsequent period (6, 
7). However, in ADHD studies with both subjective and 
objective eating disorder examination instruments, 
consistent results are lacking, although it should be noted 
that the effects of long-term methylphenidate (MPH) on 
both appetite and weight have been minimally studied. A 
recently published, double-blind, drug-placebo, cross-over 
design trial found improvements, using MPH compared to 
placebo, in rates of binge eating cessation (8). 
Decreased appetite is the most frequent adverse effect 
of stimulants, but it is not necessarily related to a decrease 
in height and BMI. The association between stimulants and 
a delay in growth is still unclear and controversial. 
Although a recent review and meta-analysis reported the 
prevalence of obesity in children/adolescents with ADHD 
is 40% higher than in healthy children/adolescents, a 
notable side effect of MPH is thought to be growth delay 
(9). 
This study evaluated the effects of MPH on eating 
patterns in Turkish children and adolescents with ADHD 
and also in healthy controls. The secondary aim of this 
study was the comparison of weight and eating behavior 
patterns between children with ADHD and MPH treatment 
and children without ADHD. In this context, we 
hypothesized that (I) MPH and ADHD would show a 
negative effect on eating patterns, and (II) would be 
associated with reduction of height, weight, and body mass 
index (BMI) in Turkish children and adolescents.  
Materials and Methods 
Study setting and subjects 
We reviewed the medical records of 152 children and 
adolescents (aged 6-18 years) with ADHD who received 
treatment with MPH for at least 1 year at the Department 
of Child and Adolescent Psychiatry at Dokuz Eylül 
University Medical School. The exclusion criteria via 
medical records included (I) positive history of diseases 
that can suppress growth, (II) past and/or current history of 
autistic spectrum disorders or mental retardation, (III) past 
and/or current history of epilepsy, brain injury, and 
cerebral palsy, and (IV) use of chronic medications which 
could affect growth (e.g. cortisol, stimulants, mood 
stabilizers). Nine participants with missing or erroneous 
entries in the data collection instruments were excluded 
from the study. 144 children and adolescents (aged 6-18 
years) who were brought to our pediatric outpatient clinic 
by parents for causes such as headaches or acute infections, 
but did not meet any diagnostic criteria, formed the healthy 
sample group. Data from both groups—287 cases—were 
analyzed after approval was obtained from the The Dokuz 
Eylul University Ethics Committee. After participiants 
were informed about the aim and method of the research, 
written consent was obtained.  
Height, weight, and BMI measurements of ADHD 
cases were obtained from hospital records. Participants 
diagnosed with K-SADS-PL by blinded professionals 
completed a data form containing questions regarding 
sociodemographic and clinical features (data about MPH 
treatment by age, duration of MPH treatment etc.), 
Wechsler Intelligence Scale for Children-Revised (WISC-
R) and Conners Parent Rating Scale-Revised Short Form 
(only for ADHD cases to support the diagnosis), and The 
Eating Disorder Examination Questionnaire (EDE-Q) (all 
participants). Weight, height, and BMI z-scores (age- and 
gender- adjusted) were collected at baseline and final 
follow-up. We also recorded weight, height, and BMI z-
scores of the healthy sample group (10) for statistical 
comparisons.   
Assessment instruments 
Sociodemographic Data Form: This form obtained 
information about age, gender, education, family type, 
socioeconomic level, home conditions, status of parents, 
background, and family history. 
Conners Parent Rating Scale-Revised Short Form 
(CPRS-RSF): This form is widely used for the assessment 
of the prevalence of ADHD and its effect on diagnosis and 
treatment. Studies on the new version are described in the 
U.S. and Canada. The validity and reliability study of the 
scale were assessed by Kaner (2013) (11). 
Eating Disorder Examination Questionnaire (EDE-Q): 
The EDE-Q is the self-report version of the Eating 
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Disorder Assessment Interview (12). In Turkish 
psychometric evaluation, the internal consistency 
coefficient was .93 and the test-retest reliability was .91 
(13). 
Stastistical Analysis 
Differences in all study variables were analysed using 
SPSS (IBM, NY) version 22. The Shapiro–Wilk test was 
used initially to ascertain that variables met the conditions 
for parametric tests. Variables that did not show normal 
distribution were evaluated by the Mann-Whitney U test. 
In the interpretation of the variables, descriptive statistical 
techniques and quantitative data analyses were used. Chi-
square analysis was used to compare categorical variables 
between groups. The Pearson correlation was used to 
determine the direction, level, and significance of 
correlations between the variables. P<0.05 was considered 
statistically significant. 
Results 
Table 1 summarizes the main features of the 
participants and the identification of the clinical 
characteristics between groups. The mean age of the 
patient group was 9.40 ± 2.60 and the mean age of the 
control group was 9.85 ± 2.26, with no difference between 
groups (t=1.544, p = 0.114). Table 1 summarizes the first 
and last follow-up visit BMIs, WISC-R scores, MPH 
duration of use (months), and MPH doses for ADHD cases. 
No differences between groups were reported in terms of 
sex, parental education level, and employment status (all 
groups).  
Table 1. The sociodemographic data of the ADHD patients and the control groups 
    ADHD 
   n = 143 
Controls 
n = 144 
p-values 
    
Age* (mean ± sds) 12.62 ± 2.44 12.85 ± 2.26 0.114 
Gender, male, n (%) 118 (82.6%)    110 (79.7%)  
Mother’s mean age (mean ± sds) 37.02 ± 3.44  35.41 ± 4.32 0.243 
Maternal education n (%)    
< 8 years 67 (46.85%)         73 (50.69%) 0.312 
> 8 years 
 

















First BMI (sds) 19.26 (3.10) 19.56 (3.32) 0.324 
Follow-up BMI (sds) 20.21 (2.75) 20.57 (2.91) 0.275 
MPH duration of use (months) (sds) 28.15 (6.2)   
MPH mean dose (mg) (sds) 25.99 (6.82)   
MPH mean dose [mg/(kg/d)] (sds) 0.89(0.14)   
WISC-R total score (sds) 89.45 (18.7) 86.25 (17.6) 0.315 
Note: ADHD; attention deficit hyperactivity disorder, n (number of patients), sds; standard deviation score, BMI; body mass index, MPH; 
methylpenidate, WISC-R; Wechsler Intelligence Scale for Children-revision, *p < 0.05; **p < 0.01. 
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Table 2 summarizes the total and subscale scores of 
ADHD and control subjects on the Eating Disorder 
Examination Questionnaire (EDE-Q) and Conners Parent 
Rating Scale-Revised Short Form (CPRS-RSF). A 
significant difference was found between the two groups in 
terms of EDE-Q- eating concerns, EDE-Q- shape concern, 
and all CPRS-RSF subscales (p <.05). There were no 
differences in other subtests between EDE-Q- weight 
concern, EDE-Q- restraint, and EDE-Q- global score (p> 
0.05). 
Table 2. Conners Parent Rating Scale-Revised Short Form (CPRS-RSF) scores of ADHD and the control group 
 
ADHD 










    t 
 
p-values 
      
EDE-Q- Global 1.02 (0.83) 0.92 (0.68)     1.716  1.153 0.250 
EDE-Q- Restraint 0.74 (1.00) 0.89 (0.94)     0.482 -1.294 0.197 
EDE-Q- Eating concern 1.03 (0.99) 0.73 (0.68)   15.277  2.964 0.003* 
EDE-Q- Shape concern 1.24 (0.92) 1.02 (0.92)     0.016  2.001 0.046* 
EDE-Q- Weight concern 1.00 (0.80) 1.03 (0.76)     0.018 -0.363 0.717 
CPRS-RSF- Oppositional 7.96 (4.42) 3.40 (2.11)   67.284 10.991 <0.001** 
CPRS-RSF- Cognitive Problems 9.90 (5.04) 2.92 (1.52)   18.604 15.594 <0.001** 




5.20 (2.84)  71.856 17.543 <0.001** 
Note: ADHD; attention deficit hyperactivity disorder, n (number of patients), SDS; standard deviation score, EDE-Q; Eating Disorder 
Examination Questionnaire, CPRS-RSF; Conners Parent Rating Scale-Revised Short Form, *p < 0.05; **p < 0.01.   
Considering the entire sample, weight-SDS 
significantly decreased at follow-up (baseline weight-SDS 
[SDS] 0.51 [1.06], follow-up: -0.21 [0.64]; p** < 0.001). 
Height-SDS [SDS] was also affected: 0.64 [1.13] at 
baseline and -0.46 (2.25) at follow-up (p** < 0.001). There 
were no significant differences in pre- and post-treatment 
BMI-SDS [SDS] z scores: baseline 0.32 [1.01], follow-up: 
-0.30 (2.56), p = 0.318. The effect of MPH on growth is 
described in detail in Table 3, including pre- and postdata 
on weight, height and BMI z-scores. 
However, considering whether the patients were 
children (6–12 years) or adolescents (13–18 years) when 
they began medication, in the group of children, height 
was slightly affected by the treatment (baseline height-
SDS [SDS]: 0.89 [1.12]; follow-up: -0.58 [2.40]; p* = 
0.008), but this effect was not observed when MPH began 
during adolescence. In those cases, height-SDS was 
slightly above the average at follow-up (baseline height-
SDS [SDS]: 0.47 [1.18], follow-up: -0.20 [0.85]; p = 
0.087). 
In the group of MPH children, weight was not affected 
by the treatment (baseline weight-SDS [SDS]: 0.70 [2.95]; 
follow-up: 0.25 [2.82]; p = 0.312), and no effect was also 
observed when MPH was started during adolescence. In 
such cases, weight-SDS was slightly above the average at 
follow-up (baseline weight-SDS [SDS]: 0.40 [1.02], 
follow-up: -0.26 [1.08]; p = 0.238). 
In the group of children, BMI was significantly affected 
by the treatment (baseline BMI-SDS [SDS]: 0.46 [1.08]; 
follow-up: -0.21 [0.59]; p** < 0.001). This effect was not 
observed when MPH began during adolescence. In such 
cases, BMI-SDS was slightly above the average at follow-
up (baseline BMI-SDS [SDS]: 0.28 [1.04], follow-up: -
0.12 [0.71]; p = 0.092) (Table 3). 
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Table 3. Comparison of height, weight and BMI at baseline and follow up data of Methylphenidate treatment by age 
                
                  Total sample (n= 143)                             Children (6–12 years) (n= 63)                Adolescents (13–18 years) (n= 80) 
                        Baseline (T1)   Follow-up (T2)        p              Baseline (T1)   Follow-up (T2)    p            Baseline (T1)   Follow-up (T2)    p 
Weight-SDS     0.51 (1.06)      -0.21 (0.64)      ** < 0.001        0.70 (2.95)       0.25 (2.82)         0.312        0.40 (1.02)      -0.26 (1.08)         0.238 
Height-SDS      0.64 (1.13)      -0.46 (2.25)      ** < 0.001        0.89 (1.12)      -0.58 (2.40)      * 0.008        0.47 (1.18)      -0.20 (0.85)         0.087 
BMI-SDS         0.32 (1.01)       -0.30 (2.56)              0.318        0.46 (1.08)     -0.21 (0.59)    **< 0.001       0.28 (1.04)      -0.12 (0.71)        0.092 
Note: BMI; body mass index, n (number of patients), SDS; standard deviation score; *p<0.05, **p<0.01. p values 
from paired t-tests   
Table 4 shows correlations between Eating Disorder 
Examination Questionnaire (EDE-Q) subscale scores, 
Conners Parent Rating Scale-Revised Short Form (CPRS-
RSF), Body mass index, MPH mean dose [mg/(kg/d)], and 
duration of use (months) for the ADHD sample. 
Correlations were significant between all CPRS-RSF 
subscale scores and the scores for EDE-Q eating concern 
(positive).mThe EDE-Q subscale scores correlated with 
one other. A statistically significant positive correlation 
was found between EDE-Q shape concern and CPRS-RSF 
subscale scores assessing inattention and cognitive 
problems. No correlations were found with BMI, MPH 
mean dose [mg/(kg/d)], and duration of use (months) 
except restraint subscale. 
               
    




This study evaluated the effects of MPH on eating 
patterns in attention deficit/hyperactivity disorder (ADHD) 
children and adolescents. A secondary aim was to compare 
the weight and eating behavior in children with ADHD and 
MPH treatment with that of children without ADHD. We 
had expected to find that individuals who take MPH for 
ADHD would be more likely to show negative effects on 
eating patterns. Moreover, we explored the association 
between MPH and growth parameters of weight, height, 
and BMI standard z-scores, but only minimal effects were 
noted in our sample. 
Previous research has associated ADHD with global 
eating disorder pathology, restraint, eating, shape, and 
weight concerns. Several mechanisms have been advanced 
to explain ADHD effects on eating patterns. According to 
one recent study (2018), children with ADHD may have 
less control while eating and thus consume more calories 
than healthy subjects. In addition, children diagnosed with 
ADHD may eat more food even when they are satiated 
compared to healthy subjects (14). Faster eating in children 
with ADHD, the inability to focus on hunger-satiety cycles, 
and the inability to perceive body stimuli may all lead to 
impaired eating-feeding patterns. 
Alternatively, the eating problems may reflect a 
complex interaction among a number of functions, 
including deterioration in executive function, eating-
appetite problems, eating problems, obesity, eating 
disorders (especially bulimia nervosa and binge eating 
disorder), attachment and family relation problems. As 
predicted, this interaction is more frequent and more 
complicated in women with ADHD than in men. 
Therefore, it is important to focus on the problems related 
to nutrition-appetite-eating and not to overlook a possible 
ADHD diagnosis, especially in female children and 
adolescents, given that obesity, under-threshold eating 
disorders (ADHD, bulimia nervosa and binge eating 
disorder risk especially during adolescence), and manifest 
eating disorders are more common in female adolescents. 
For this reason, early diagnosis and treatment are vitally 
importance for those with ADHD. 
Several interpretations of our results are possible. It is 
well-known that ADHD may not directly cause eating 
disorders but, in many cases, may cause subthreshold 
eating disorders and impaired eating patterns (15). 
Therefore, the associations between EDEQ and all CPRS-
RSF subscale scores that hint at increased disordered eating 
patterns as another comorbidity in individuals with ADHD 
might initially seem legitimate. However, it remains 
uncertain whether the altered eating patterns that result 
from MPH reflect a deliberate decision to compensate for 
it, or whether the compensation response is automatic 
(rather than deliberate). For example, shape and weight 
concerns among these individuals are consistent with prior 
research in those individuals who engage in disordered 
eating behaviors and tend to have higher body image 
concerns (16). In our study, there was no correlation 
between the MPH mean dose [mg/(kg/d)], the duration of 
use (months), and the core characteristics of eating 
disorders except restraint subscale of EDE Q. 
Whereas MPH raises brain synaptic dopamine, which 
has been shown to induce anorexia and weight loss, it is 
generally considered a safe medication. Research on 
energy intake during the administration of MPH has been 
limited, but studies have shown effects on body weight 
and/or eating behavior that are consistent with the 
hypothesis that dopamine may play a role in the 
development or perpetuation of human obesity (17). 
Attention deficit and impulsivity symptom clusters in 
ADHD may increase the development of obesity and binge 
eating. The early treatment of ADHD with 
psychostimulants or atomoxetine may reduce nutritional 
difficulties associated with obesity and binge eating, loss 
of control while eating, and impairments in reward-
motivation systems (18). 
The significant decrease in z-scores for height and 
weight was observed in the overall sample, but the decline 
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was not observed in all subgroups suggested in the clinical 
literature (19, 20). Several possible mechanisms that might 
explain the effects of MPH on height and weight include 
inhibition of growth hormone, nutritional state differences, 
and parental height values. 
Our study focused on the effect of psychostimulants in 
the different age subgroups, i.e., children (6–12 years) and 
adolescents (13–18 years). In the children subgroup, height 
and BMI were significantly reduced by the treatment. 
Given this finding, young patients using MPH should be 
closely monitored. Few studies have examined the 
relationships between the age of onset, the duration, and 
the growth parameters for the ADHD sample. The present 
study suggests that younger age at first stimulant use was 
associated with a decline in anthropometric scores. Our 
findings that there was no significant delay in the rate of 
physical maturation do not align with the findings of 
Gustafsson et al. (2010), which suggests that children with 
ADHD are less mature at baseline as they show a rapid 
maturation catch-up (21). The possible reasons for these 
differences may include nutritional status or hormonal 
mechanisms which can modify the relationship between 
growth and physical maturation.  
Limitations 
Limitations of our study need to be considered. 
Participants with no clinically diagnosed possible 
conditions associated with growth retardation were 
selected for the study sample, but differences between the 
health conditions of the participants, which may affect the 
anthropometric values, may have occurred. Also, we did 
not evaluate parental anthropometric values, socio-
economic status, ethnicity, and genetic factors of the 
ADHD group, which may have influenced our results. 
Finally, we did not consider comorbid features such as 
mood disorders or mental retardation that can be associated 
with eating patterns. Because other medications can also 
influence growth parameters; the impact of such factors 
remains unknown. 
Future prospective and longitudinal studies would 
allow a deeper understanding of whether and how 
complexities of growth parameters are affected by ADHD. 
Conclusions 
The current study evaluated the effects of MPH and 
ADHD on eating patterns and growth patterns in Turkish 
Children and Adolescents. The results may have clinical 
implications for monitoring the core characteristics of 
eating disorders and growth parameters in ADHD patients. 
Our findings add to the growing literature regarding MPH, 
eating disorders, and anthropometric values, with our 
findings concluding that MPH may not be associated with 
the reduction of growth velocity and disordered eating 
behaviors. 
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